# Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population

> **NCT05480436** · PHASE4 · UNKNOWN · sponsor: **China National Biotec Group Company Limited** · enrollment: 1200 (estimated)

## Conditions studied

- Hemolysis
- COVID-19

## Interventions

- **BIOLOGICAL:** coadministration
- **BIOLOGICAL:** COVID-19 vaccine
- **BIOLOGICAL:** IIV4+PPV23

## Key facts

- **NCT ID:** NCT05480436
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-05
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2022-08-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05480436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05480436, "Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05480436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*